Cancer vaccines are becoming an increasingly attractive focus of study, but there are still perils and pitfalls along the way to success. Two recent studies have looked at ways to get around these, focusing on experimental cancer vaccines boosted by existing drugs.
Abbott Labs ($ABT) doesn't do a lot of deals compared with some of its Big Pharma rivals. But when the company inks a deal, it isn't afraid of using some big numbers. Abbott pledged $450 million just
Biogen Idec and its partner Abbott Labs have taken the wraps off the top-line data from a Phase IIb study of daclizumab, touting some promising results for the once-monthly treatment of multiple